Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 13/20 | 0.53 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11076736 | 0.84 | CCR2 (0.47) | ADAM17CCR2SLC6A4SLC6A3 | |
| SCHEMBL11075435 | 0.81 | ADAM17 (0.49) | ADAM17CCR2 | |
| SCHEMBL5792422 | 0.81 | SLC6A4 (0.47) | ADAM17SLC6A4SLC6A3 | |
| SCHEMBL13734024 | 0.81 | ADAM17 (0.43) | ADAM17CCR2SLC6A4SLC6A3 | |
| SCHEMBL24389394 | 0.81 | ADAM17 (0.43) | ADAM17CCR2SLC6A4SLC6A3 | |
| SCHEMBL24389415 | 0.81 | ADAM17 (0.43) | ADAM17CCR2SLC6A4SLC6A3 | |
| SCHEMBL15468836 | 0.81 | ADAM17 (0.46) | ADAM17SLC6A4SLC6A3 | |
| SCHEMBL11078227 | 0.80 | OPRM1 (0.53) | ADAM17SLC6A4SLC6A3 | |
| SCHEMBL2475551 | 0.80 | ADAM17 (0.45) | ADAM17SLC6A4SLC6A3 | |
| SCHEMBL11078230 | 0.80 | OPRM1 (0.53) | ADAM17SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161863-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | MCKINNEY ANTHONY ALEXANDER (US) | 2021-06-03 | — | — | US | disclosed |
| US-20180256542-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2018-09-13 | — | — | US | disclosed |
| US-9770436-B2 | Polymorphs of azabicyclohexane | EUTHYMICS BIOSCIENCE, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160346249-A1 | USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160008324-A1 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | ETHISMOS RESEARCH, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9139521-B2 | Polymorphs of azabicyclohexane | EUTHYMICS BIOSCIENCE, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8765801-B2 | Polymorphs of azabicyclohexane | EUTHYMICS BIOSCIENCE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140039029-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20130345279-A1 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | ETHISMOS RESEARCH, INC. | 2013-12-26 | — | — | US | disclosed |
| EP-2646019-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | Euthymic Bioscience, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075473-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | EUTHYMIC BIOSCIENCE, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120136038-A1 | Novel Polymorphs Of Azabicyclohexane | ETHISMOS RESEARCH, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20110294847-A1 | Novel Polymorphs Of Azabicyclohexane | ETHISMOS RESEARCH, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20090326245-A1 | Novel Polymorphs of Azabicyclohexane | ETHISMOS RESEARCH, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1786417-A4 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | DOV PHARMACEUTICAL INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
| EP-1786417-A2 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | DOV Pharmaceutical, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070043100-A1 | Novel polymorphs of azabicyclohexane | ETHISMOS RESEARCH, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2006023659-A2 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | DOV PHARMACEUTICAL, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | ADAM17 4084/4885CCR2 372/4885SLC6A4 2230/4885 |
| US-20130345279-A1 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | CYP3A43, CYP2D6, CYP26B1 | ADAM17 3439/4885CCR2 1654/4885SLC6A4 1901/4885 |
| US-20090326245-A1 | Novel Polymorphs of Azabicyclohexane | CYP3A43, CYP2D6, CYP26B1 | ADAM17 3439/4885CCR2 1654/4885SLC6A4 1901/4885 |
| US-20210161863-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | ADAM17 3287/4885CCR2 1095/4885SLC6A4 25/4885 |
| US-20140039029-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | ADAM17 3287/4885CCR2 1095/4885SLC6A4 25/4885 |
| US-20160008324-A1 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | CYP3A43, CYP2D6, CYP26B1 | ADAM17 3439/4885CCR2 1654/4885SLC6A4 1901/4885 |
| US-20110294847-A1 | Novel Polymorphs Of Azabicyclohexane | CYP3A43, CYP2D6, CYP26B1 | ADAM17 3439/4885CCR2 1654/4885SLC6A4 1901/4885 |
| US-20120136038-A1 | Novel Polymorphs Of Azabicyclohexane | CYP3A43, CYP2D6, CYP1B1 | ADAM17 3407/4885CCR2 1423/4885SLC6A4 1933/4885 |
| US-20160346249-A1 | USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | CYP2D6, MAOB, HTR1A | ADAM17 1624/4885CCR2 1495/4885SLC6A4 89/4885 |
| US-20070043100-A1 | Novel polymorphs of azabicyclohexane | CYP3A43, CYP2D6, CYP26B1 | ADAM17 3439/4885CCR2 1654/4885SLC6A4 1901/4885 |
| US-20180256542-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | ADAM17 3287/4885CCR2 1095/4885SLC6A4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.